Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:22 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 1,757 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Major Depressive Disorders Clear all

Conditions: Schizophrenia, Schizoaffective Disorder, Bipolar Disorder With Psychotic Features, Major Depression With Psychotic Features, Psychosis Not Otherwise Specified (NOS)
Interventions: Not listed
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 75 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Major Depressive Disorder
Interventions: Psilocybin; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 75 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Depression
Interventions: Duloxetine, Escitalopram, BMS-820836 Placebo, BMS-820836; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 976 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 48
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Chino, California + 41 more

Conditions: Heart Failure, Depressive Disorder, Major
Interventions: Stepped care for depression; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 25 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Obsessive Compulsive Disorder, Major Depressive Disorder, Epilepsy
Interventions: Deep Brain Stimulator; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Boston, Massachusetts • Charlestown, Massachusetts

Conditions: Left Rostromedial Prefrontal Cortex - Accelerated Intermittent Theta Burst, Left Dorsolateral Prefrontal Cortex - Accelerated Intermittent Theta Burst, Left Primary Somatosensory Cortex - Accelerated Intermittent Theta Burst
Interventions: Accelerated Intermittent Theta Burst Transcranial Magnetic Stimulation; Device
Lead sponsor: Florida State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Major Depressive Disorder
Interventions: Quetiapine fumarate; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 56
States / cities: Phoenix, Arizona • El Centro, California • Irvine, California + 53 more

Conditions: Major Depressive Disorder, Substance Use Disorders
Interventions: Peer Activate, Peer-delivered non-specific services; Behavioral
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Depression, Depressive Disorder, Depressive Disorder, Major, Depression, Bipolar, Depressive Episode
Interventions: Mental Health DNA Insight Test (Pathway Genomics), Sham Test; Diagnostic Test
Lead sponsor: San Diego Veterans Healthcare System; Federal
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: San Diego, California

Conditions: Depressive Disorder, Major
Interventions: Desvenlafaxine Succinate Sustained-Release (DVS SR), Placebo, Duloxetine 60 mg/day; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 638 participants
Timeline: 2006 – 2007
U.S. locations: 22
States / cities: Beverly Hills, California • Burbank, California • Encino, California + 19 more

Conditions: Depression, Depressive Disorder, Depressive Disorder, Treatment-resistant, Depressive Disorder, Major
Interventions: LFMS; Device
Lead sponsor: Tal Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 12
States / cities: Garden Grove, California • Lemon Grove, California • Oakland, California + 9 more

Conditions: Major Depressive Disorder
Interventions: Centanafadine, Escitalopram, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 337 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 62
States / cities: Yuma, Arizona • Bryant, Arkansas • Glendale, California + 53 more

Conditions: Depression
Interventions: Not listed
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 64 Years
Enrollment: 87 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 3
States / cities: Boston, Massachusetts • Cambridge, Massachusetts • Charlestown, Massachusetts

Conditions: Bone Diseases, Metabolic, Depression, Involutional, Osteoporosis
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: Not listed
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Depression
Interventions: Venlafaxine XR, Placebo, JNJ26489112; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 14
States / cities: Arcadia, California • Escondido, California • San Diego, California + 11 more

Conditions: Major Depressive Disorder
Interventions: memantine, Placebo; Drug
Lead sponsor: Jerrry L Lewis; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Major Depressive Disorder (MDD)
Interventions: Accelerated rTMS treatment; Device
Lead sponsor: NeuroQore Inc.; Industry
Eligibility: 22 Years to 85 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: San Jose, California

Conditions: Suicidal Ideation, Suicide Attempt, Suicidal Behavior, Depression / Major Depressive Disorder, Hopelessness, Neurobiological
Interventions: CAMS; Behavioral
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 14 Years to 24 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Depressive Disorder, Major, Bipolar Disorder, Schizo Affective Disorder, Schizophrenia
Interventions: CAT, R-CAT; Behavioral
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Major Depressive Disorder
Interventions: Neuropsychological Educational Approach to Cognitive Remediation (NEAR, termed Cognitive Remediation plus Bridging); Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Major Depressive Disorder
Interventions: Neuronavigated rTMS, Sham rTMS; Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Stanford, California

Conditions: Major Depressive Diorder
Interventions: Psilocybin (drug), cognitive behavioral therapy, Minimal supportive therapy; Drug · Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 21 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Depression, Suicidal Ideation
Interventions: Paroxetine CR for Major Depressive Episode, Bupropion XL for Major Depressive Episode; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Major Depressive Disorder, Anhedonia
Interventions: Not listed
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 45 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Belmont, Massachusetts • Boston, Massachusetts

Search by objective public record fields.

Social Cognition in Longstanding Psychosis

Effects of Psilocybin in Major Depressive Disorder

Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression

Stepped Care for Depression in Heart Failure

ON/OFF Stimulation and Reward Motivation in Patients With Deep Brain Stimulators

Causal Role of Rostromedial Prefrontal Cortex for Positive Savoring in Depression

Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in Combination With an Antidepressant in the Treatment of Major Depressive Disorders

Peer-Delivered Behavioral Activation in a CCBHC

Pharmacogenetic Implementation Trial in Veterans With Treatment Refractory Depression

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder

Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)

Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder

Understanding Brain Reward Responses in Individuals With Major Depressive Disorder

Use of Bone Biopsy to Better Understand the Causes of Decreased Bone Mineral Density in Depression

A Safety and Efficacy Study of JNJ26489112 in Patients With Treatment-Resistant Major Depressive Disorder

The Impact of Memantine on Electroconvulsive Therapy (ECT): Will it Improve Response and Protect Against Cognitive Problems?

NQ TMS for MDD Therapy Using 1 Day x 3 Sessions Protocol for Adult Patient

Neural Correlates of Suicidal Behavior in Youth

In-person vs. Remote Wellness Support

A Novel Cognitive Remediation Intervention Targeting Poor Decision-making and Depression in Veterans at High Risk for Suicide: A Safe, Telehealth Approach During the COVID-19 Pandemic

Probing the Dorsolateral Prefrontal Cortex and Central Executive Network for Improving Neuromodulation in Depression

RCT of Psilocybin-assisted CBT for Depression

Paroxetine/Bupropion in Depression With Suicide Attempt or Thoughts: fMRI Study

Dopamine Neurotransmission in Major Depression